Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus-co-infected patients: Still a role for liver biopsy? [4]

AIDS

Volumn 18, Issue 12, 2004, Pages 1746-1748

  Merchante, Nicolás ^a   Macías, Juan ^a   Palacios, Rosa B ^a   Mira, José A ^a   García García, José A ^a   Lozano, Fernando ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER BIOPSY; LIVER FIBROSIS; PRIORITY JOURNAL; SUPERINFECTION;

ADULT; BIOPSY; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE;

EID: 4143054671     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131389.83844.8a     Document Type: Letter

References (9)

1. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004, 18:1-12.
2. Pérez-Olmeda M, Núñez M, Romero M, González J, Arribas J, Soriano V. Pegylated interferon alpha 2b plus ribavirin as a therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17:1023-1028.
3. Torriani FJ, Rockstroh I, Rodríguez-Torres M, Lissen E, González J, Lazzarin A, et al. Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alfa-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. In: 11th Conference on Retroviruses and Opportunistics Infections. San Francisco, February 2004 [Abstract 112].
4. Perrone C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIVco-infected patients. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [Abstract 117LB].
5. Martínez-Sierra C., Arizcorreta A, Díaz F, Roldan R, Martín-Herrera L, Pérez-Guzmán E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrosis in patients coinfected with HCV and HIV. Clin Infect Dis 2003, 36:491-498.
6. Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a european collaborative study. Clin Infect Dis 2004, 38:128-133.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
8. Berenguer J, Miralles P. Liver fibrosis in HIV-infected patients who are candidates for treatment of chronic hepatitis C. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, October 2002 [Abstract H-1276].
9. Matthews G, Dore G. Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?' [Letter]. AIDS 2003, 17:2675-2676.